03:56 AM EDT, 07/03/2025 (MT Newswires) -- Novartis AG ( NVS ) said Thursday that a phase 3 study of its drug Cosentyx combined with a 26-week steroid taper in adults with newly diagnosed or relapsing giant cell arteritis did not meet its primary endpoint of statistically significant improvement in sustained remission at 52 weeks compared with placebo plus a 52-week steroid taper.

While secondary outcomes also did not show statistical superiority, they showed "numerically better outcomes" compared to the placebo, the company said.

Novartis ( NVS ) said it will complete a full evaluation of the study data and share the results later.

Giant cell arteritis is a common form of vasculitis that may cause vision loss and life-threatening aneurysms.